Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.63)
# 825
Out of 5,143 analysts
14
Total ratings
75%
Success rate
18.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARMP Armata Pharmaceuticals | Initiates: Buy | $15 | $5.98 | +150.84% | 1 | Jan 5, 2026 | |
| SYRE Spyre Therapeutics | Upgrades: Buy | $64 | $33.99 | +88.29% | 2 | Dec 1, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Hold | n/a | $14.03 | - | 2 | Nov 11, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $46 | $40.79 | +12.77% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $20.37 | +17.82% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $6.35 | +325.20% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $4.70 | +729.79% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $15.91 | +88.56% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $12.20 | +88.52% | 1 | Mar 13, 2025 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $27.50 | +67.27% | 1 | Sep 19, 2024 |
Armata Pharmaceuticals
Jan 5, 2026
Initiates: Buy
Price Target: $15
Current: $5.98
Upside: +150.84%
Spyre Therapeutics
Dec 1, 2025
Upgrades: Buy
Price Target: $64
Current: $33.99
Upside: +88.29%
Intellia Therapeutics
Nov 11, 2025
Downgrades: Hold
Price Target: n/a
Current: $14.03
Upside: -
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $40.79
Upside: +12.77%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $20.37
Upside: +17.82%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $6.35
Upside: +325.20%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $4.70
Upside: +729.79%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $15.91
Upside: +88.56%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $12.20
Upside: +88.52%
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $27.50
Upside: +67.27%